Antibiotic susceptibility of invasive Haemophilus influenzae strains in Canada

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 4, 2008, Pages 1551-1552

  Sill, Michelle L ^a   Tsang, Raymond S W ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAMASE; CEFACLOR; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANADA; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; NONHUMAN; PRIORITY JOURNAL;

AMPICILLIN; AMPICILLIN RESISTANCE; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CANADA; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; SEROTYPING;

EID: 42049117327     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01580-07     Document Type: Article

References (11)

1. Bath, S., K. Bisgard, T. Murphy, K. Shutt, N. Rosenstein, and C. Ohuabunwo. 2002. Progress towards elimination of Haemophilus influenzae type b invasive disease among infants and children - United States, 1998-2000. MMWR Morb. Mortal. Wkly. Rep. 51:234-237.
2. Dworkin, M. S., L. Park, and S. M. Borchardt. 2007. The changing epidemiology of invasive Haemophilus influenzae disease, especially in persons ≥65 years old. Clin. Infect. Dis. 44:810-816.
3. Falla, T. J., D. W. Crook, L. N. Brophy, D. Maskell, J. S. Kroll, and E. R. Moxon. 1994. PCR for capsule typing of Haemophilus influenzae. J. Clin. Microbiol. 32:2382-2386.
4. Gunn, B. A., J. B. Woodall, J. F. Jones, and C. Thornsberry. 1974. Ampicillin-resistant Haemophilus influenzae. Lancet ii:845.
5. Heilmann, K. P., C. L. Rice, A. L. Miller, N. J. Miller, S. E. Beekmann, M. A. Pfaller, S. S. Richter, and G. V. Doern. 2005. Decreasing prevalence of β-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob. Agents Chemother. 49:2561-2564.
6. Jordens, J. Z., and M. P. E. Slack. 1995. Haemophilus influenzae: then and now (a review). Eur. J. Clin. Microbiol. Infect. Dis. 14:935-948.
7. Karpanoja, P., A. Nissinen, P. Huovinen, and H. Sarkkinen. 2004. Disk diffusion susceptibility testing of Haemophilus influenzae by NCCLS methodology using low-strength ampicillin and co-amoxiclav discs. J. Antimicrob. Chemother. 53:660-663.
8. National Committee for Clinical Laboratory Standards. 2003. NCCLS document M2-A8 volume 23, no. 1, Performance standards for antimicrobial disk susceptibility tests, approved standard, 8th ed. National Committee for Clinical Laboratory Standards, Villanova, PA.
9. Scheifele, D., S. Halperin, W. Vaudry, T. Jadavji, B. Tan, B. Law, N. LeSaux, L. Ford-Jones, M. Lebel, D. Moore, P. Dery, R. Morris, J. Waters, J. Embree, and W. Wallop. 2001. Historic low Haemophilus influenzae type b case tally - Canada 2000. Can. Commun. Dis. Rep. 27:149-150.
10. Tsang, R. S. W., M. L. Sill, S. J. Skinner, D. K. Law, J. Zhou, and J. Wylie. 2007. Characterization of Haemophilus influenzae disease in Manitoba, Canada, 2000-2006: invasive disease due to non-type b strains. Clin. Infect. Dis. 44:1611-1614.
11. Zhanel, G. G., L. Palatnick, K. A. Nichol, D. E. Low, D. J. Hoban, and the CROSS Study Group. 2003. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47:1875-1881.